To date, the impact of CAR-T cell therapies has expanded across a range of haematologic malignancies, primarily targeting CD19 and CD20 on B cell-derived cancers, and B cell maturation antigen (BCMA) on multiple myeloma (Table 1). This evidence concerns the gene TNFRSF17 and AL amyloidosis.